Resolution of pretibial myxedema with teprotumumab in a patient with Graves disease.
作者信息
Varma Aakaash, Rheeman Charles, Levitt Jacob
机构信息
College of Medicine, SUNY Downstate Health Sciences University, Brooklyn, New York.
Department of Dermatology, The Mount Sinai Hospital, New York, New York.
出版信息
JAAD Case Rep. 2020 Sep 15;6(12):1281-1282. doi: 10.1016/j.jdcr.2020.09.003. eCollection 2020 Dec.
Abstract
摘要
相似文献
1
Resolution of pretibial myxedema with teprotumumab in a patient with Graves disease.
JAAD Case Rep. 2020 Sep 15;6(12):1281-1282. doi: 10.1016/j.jdcr.2020.09.003. eCollection 2020 Dec.
2
Graves' disease complicated by concurrent thyroid eye disease and pretibial myxedema successfully treated with teprotumumab.
Clin Case Rep. 2022 Nov 19;10(11):e6621. doi: 10.1002/ccr3.6621. eCollection 2022 Nov.
3
Orbital decompression in Graves' ophthalmopathy associated with pretibial myxedema.
J Endocrinol Invest. 1993 Jun;16(6):433-7. doi: 10.1007/BF03348875.
4
Pretibial myxedema in a euthyroid patient: a case report.
Thyroid Res. 2021 Mar 1;14(1):4. doi: 10.1186/s13044-021-00096-z.
5
Pretibial myxedema as the initial manifestation of Graves' disease.
J Eur Acad Dermatol Venereol. 2002 Jul;16(4):380-3. doi: 10.1046/j.1468-3083.2002.00567.x.
6
TSH and TSH receptor antibody-binding sites in fibroblasts of pretibial myxedema are related to the extracellular domain of entire TSH receptor.
Clin Immunol Immunopathol. 1994 Apr;71(1):113-20. doi: 10.1006/clin.1994.1059.
7
Pretibial mucin. Histologic patterns and clinical correlation.
Arch Dermatol. 1993 Sep;129(9):1152-6. doi: 10.1001/archderm.129.9.1152.
8
Elephantiasic pretibial myxedema in a patient with graves disease that resolved after 131I treatment.
Clin Nucl Med. 2014 Aug;39(8):758-9. doi: 10.1097/RLU.0000000000000459.
9
Euthyroid pretibial myxedema.
Am J Med. 1987 Feb;82(2):318-20. doi: 10.1016/0002-9343(87)90077-5.
10
Pretibial myxedema and high-dose intravenous immunoglobulin treatment.
Thyroid. 1994 Winter;4(4):399-408. doi: 10.1089/thy.1994.4.399.
引用本文的文献
1
Rapid response of thyroid eye disease, peripheral edema, and acropathy to teprotumumab infusion.
Am J Ophthalmol Case Rep. 2024 Mar 2;34:102031. doi: 10.1016/j.ajoc.2024.102031. eCollection 2024 Jun.
2
Teprotumumab for Treatment of Pretibial Myxedema.
JCEM Case Rep. 2023 Jan 23;1(1):luac037. doi: 10.1210/jcemcr/luac037. eCollection 2023 Jan.
3
[An integrated approach to the treatment of pretibial myxedema based on pulse therapy with prednisolone and electrical neuromyostimulation (FREMS-therapy) in a patient with Graves' disease and thyroid eye disease].
Probl Endokrinol (Mosk). 2023 Aug 30;69(4):32-37. doi: 10.14341/probl12888.
4
Dermatologic manifestations of thyroid disease: a literature review.
Front Endocrinol (Lausanne). 2023 May 12;14:1167890. doi: 10.3389/fendo.2023.1167890. eCollection 2023.
5
Graves' disease complicated by concurrent thyroid eye disease and pretibial myxedema successfully treated with teprotumumab.
Clin Case Rep. 2022 Nov 19;10(11):e6621. doi: 10.1002/ccr3.6621. eCollection 2022 Nov.
6
Thyroid dermopathy responds to teprotumumab therapy.
Endocrinol Diabetes Metab Case Rep. 2022 Mar 1;2022. doi: 10.1530/EDM-21-0201.
7
Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy.
Proc Natl Acad Sci U S A. 2021 Dec 28;118(52). doi: 10.1073/pnas.2114244118.
8
Infusion Center Guidelines for Teprotumumab Infusions: Informed Consent, Safety, and Management of Side Effects.
J Infus Nurs. 2021;44(6):331-338. doi: 10.1097/NAN.0000000000000446.
9
A case of pretibial myxedema treated with teprotumumab.
JAAD Case Rep. 2021 Sep 1;16:134-136. doi: 10.1016/j.jdcr.2021.08.026. eCollection 2021 Oct.
10
Insulin-Like Growth Factor Pathway and the Thyroid.
Front Endocrinol (Lausanne). 2021 Jun 4;12:653627. doi: 10.3389/fendo.2021.653627. eCollection 2021.
本文引用的文献
1
Teprotumumab for the Treatment of Active Thyroid Eye Disease.
N Engl J Med. 2020 Jan 23;382(4):341-352. doi: 10.1056/NEJMoa1910434.
2
Electrosurgical debulking of pretibial myxedema of the foot.
Dermatol Online J. 2019 Feb 15;25(2):13030/qt4hb7q330.
3
Pretibial myxedema: pathophysiology and treatment options.
Am J Clin Dermatol. 2005;6(5):295-309. doi: 10.2165/00128071-200506050-00003.
4
Dermopathy of Graves' disease (pretibial myxedema): long-term outcome.
J Clin Endocrinol Metab. 2002 Feb;87(2):438-46. doi: 10.1210/jcem.87.2.8220.
Zotero 插件